Harbin Pharmaceutical Group Co (600664.SS) Stock Price
Harbin Pharmaceutical Group Co Price
Revenue has compounded at 2.9% per year over the past 19 years to 15.96 B CNY. Earnings per share have declined at 2.4% per year over the last 19 years. Harbin Pharmaceutical Group Co's net margin stands at 2.3%, broadly stable from 2.9% several years earlier. Harbin Pharmaceutical Group Co currently offers a dividend yield of about 7.23%. The payout ratio is around 367% of earnings. The dividend has grown at 23.8% per year over the past 10 years. Analysts set a median price target of 4.71 CNY, implying 31.9% below the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Harbin Pharmaceutical Group Co stock price
Harbin Pharmaceutical Group Co business model & stock analysis
Frequently asked questions about Harbin Pharmaceutical Group Co
Analysts currently set an average price target of 4.71 CNY for the Harbin Pharmaceutical Group Co stock (median: 4.71 CNY), implying -31.9 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Harbin Pharmaceutical Group Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Harbin Pharmaceutical Group Co to generate revenue of 16.40 B CNY and earnings per share of 0.24 CNY.
Converted at the current exchange rate, the Harbin Pharmaceutical Group Co share trades at 0.92 EUR (6.92 CNY).
The Harbin Pharmaceutical Group Co share (600664.SS) is listed on 1 stock exchanges, including: Shanghai (600664.SS).
The expected revenue of Harbin Pharmaceutical Group Co is 16.40 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Harbin Pharmaceutical Group Co is 604.44 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Harbin Pharmaceutical Group Co is currently 28.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harbin Pharmaceutical Group Co stock.
The price-to-sales ratio (P/S) of Harbin Pharmaceutical Group Co is currently 1.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harbin Pharmaceutical Group Co stock.
The Eulerpool Quality Score for Harbin Pharmaceutical Group Co is 2/10.
The ISIN of Harbin Pharmaceutical Group Co is CNE0000009T3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Harbin Pharmaceutical Group Co is 600664.SS. The ticker symbol is used to trade Harbin Pharmaceutical Group Co shares on the stock exchange.
Harbin Pharmaceutical Group Co stock
Harbin Pharmaceutical Group Co Peer Group
Harbin Pharmaceutical Group Co Ticker
Harbin Pharmaceutical Group Co FIGI
All fundamentals and in-depth analysis of Harbin Pharmaceutical Group Co
Our stock analysis for Harbin Pharmaceutical Group Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harbin Pharmaceutical Group Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.